BeiGene Presentations at the 2023 ASCO Annual Meeting Reinfo

Highlights from early- and late-stage pipeline include -- combination data for cornerstone therapies BRUKINSA and tislelizumab -- early results for OX40 agonist BGB-A445 and BCL-2 inhibitor BGB-11417 BeiGene

Related Keywords

United States , Switzerland , Canada , Fan Wang , Fujian , China , United Kingdom , Cambridge , Cambridgeshire , Chicago , Illinois , Australia , Beijing , South Korea , American , Great Britain , Kyle Blankenship , Shuaishuai Chen , Yutong Zhu , Yanwen Ma , Hai Xue , Xuebing Sun , Gewinn Nur , Ying Guo , Haiying Xu , Yunhang Guo , Xuesong Liu , Zhiwei Wang , Taichang Zhang , Lai Wang , Haipeng Xu , Yuan Hong , Zhenzhen Cheng , Kevin Mannix , Haimei Xing , Exchange Commission , European Union , American Society Of Clinical Oncology , Clinical Oncology , Annual Meeting , Global Head , Business Wire , Medicines Continue , Demonstrate Consistent Safety , North American , Human Results Show Promise , Key Pipeline , Prescribing Information , Patient Information , Looking Statements , Private Securities Litigation Reform Act , Yin Guo , Xiaomin Song ,